{"id":"tqb2930-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TQB2930 works by interfering with the growth and spread of cancer cells, but the exact mechanism is not well understood.","oneSentence":"TQB2930 is a chemotherapy drug that targets cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:32.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":521367,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQB2930+ chemotherapy","genericName":"TQB2930+ chemotherapy","companyName":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQB2930 is a granulocyte colony-stimulating factor receptor agonist used in combination with chemotherapy for the treatment of HER2-positive Advanced Breast Cancer. It is also being studied for its potential in treating other conditions such as Advanced Solid Tumor, Metastatic Breast Cancer, Recurrent Breast Cancer, and Advanced Malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}